Management of Elevated Alkaline Phosphatase

Diagnostic Approach

The first step in managing elevated ALP is to confirm that it is of hepatobiliary origin by measuring gamma-glutamyl transferase (GGT) and/or performing ALP isoenzyme fractionation, as recommended by the American Gastroenterological Association 1, 2
ALP can originate from tissues other than the liver, most commonly from bone, but also from intestine and other sources, highlighting the importance of determining the source of elevated ALP 1

Cholestatic liver diseases, such as Primary Biliary Cholangitis and Primary Sclerosing Cholangitis, can cause elevated ALP, and the American Association for the Study of Liver Diseases recommends ursodeoxycholic acid as first-line therapy for Primary Biliary Cholangitis 1, 3
Drug-induced liver injury (DILI) is a common cause of elevated ALP, and the National Institute of Diabetes and Digestive and Kidney Diseases recommends identifying and discontinuing the offending drug 2, 3

Measuring GGT and/or performing ALP isoenzyme fractionation can help determine the source of elevated ALP, with a hepatobiliary source likely if GGT is also elevated, as suggested by the European Association for the Study of the Liver 1, 2
Evaluating other liver function tests, such as ALT, AST, and bilirubin, and obtaining appropriate imaging, such as ultrasound, MRI, or MRCP, can help assess for biliary obstruction or liver lesions 2, 3, 4

For cholestatic liver diseases, monitoring ALP levels is important to assess treatment response, and the American Association for the Study of Liver Diseases recommends using ALP as a marker of disease activity and treatment response 1, 3, 5
For drug-induced liver injury, monitoring liver tests at appropriate intervals is crucial, and the National Institute of Diabetes and Digestive and Kidney Diseases recommends monitoring within 2-5 days for hepatocellular DILI and 7-10 days for cholestatic DILI 2, 3, 6

After treatment initiation, a subject's new stable nadir level of ALP should be used to monitor response and assess potential DILI, with a >50% reduction from baseline considered a significant response, as recommended by the American Gastroenterological Association 5
In patients with renal cell carcinoma, elevated ALP may indicate bone metastases, and a bone scan should be considered if accompanied by bone pain, as suggested by the American Urological Association 7, 8

A normal alkaline phosphatase activity does not exclude diagnoses such as Primary Sclerosing Cholangitis (PSC) in patients with liver disease 9
Transabdominal ultrasound may be normal in conditions like PSC, although bile duct wall thickening and/or focal bile duct dilatations are often identified in patients with PSC 9
In PSC, elevation of serum alkaline phosphatase is the most common biochemical abnormality, though a normal ALP does not exclude the diagnosis 9

Patients with elevated alkaline phosphatase and/or bilirubin should undergo biliary imaging to assess for biliary obstruction, as recommended by the American Gastroenterological Association 10
For grade 3 hepatitis (AST/ALT >5–20 ULN) related to immune checkpoint inhibitors, discontinuation of the immune checkpoint inhibitor and initiation of glucocorticoids at 1–2 mg/kg methylprednisolone is recommended, according to the American Gastroenterological Association 10
For grade 4 hepatitis (AST/ALT >20 ULN or total bilirubin >10 ULN) related to immune checkpoint inhibitors, permanent discontinuation of the immune checkpoint inhibitor and starting 2 mg/kg/day methylprednisolone is recommended, as per the American Gastroenterological Association 10

For patients with autoimmune hepatitis overlap syndromes, monitoring of ALP is recommended as it may not normalize rapidly with immunosuppressive treatment, according to the British Society of Gastroenterology 11
In X-linked hypophosphataemia, regular monitoring of ALP (total serum ALP in children and bone-specific ALP in adults) is recommended by the International Society of Nephrology 12 and the Kidney Disease: Improving Global Outcomes (KDIGO) 13
In patients with overlap syndromes (AIH/PBC or AIH/PSC), management should address both component diseases, as suggested by the British Society of Gastroenterology 11

The European Association for the Study of the Liver recommends performing MRCP if ultrasound is non-diagnostic and clinical suspicion of biliary obstruction remains high 14
The American Society of Nephrology suggests that in CKD patients, elevated ALP is common and associated with increased mortality risk, with a mean ALP level of 36.6 ± 35.7 ng/mL 15

The European Association for the Study of the Liver recommends treating Primary Biliary Cholangitis with ursodeoxycholic acid as first-line therapy, and monitoring ALP levels to assess treatment response, with a >50% reduction from baseline considered significant 14
The European Association for the Study of the Liver suggests that in overlap syndromes, ALP may not normalize rapidly with immunosuppressive treatment, and this should not prompt premature treatment changes 14

The National Kidney Foundation recommends monitoring total serum ALP in children and bone-specific ALP in adults as part of CKD-MBD management, with elevated ALP associated with increased mortality risk in CKD patients 15